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BACKGROUND: Concerned over the risk of Zika virus (ZIKV) transfusion transmission, public health agencies recommended the implementation of mitigation strategies for its prevention. Those strategies included the use of pathogen inactivation for the treatment of plasma and platelets. The efficacy of amotosalen/ ultraviolet A to inactivate ZIKV in plasma had been previously demonstrated, and the efficacy of inactivation in platelets with the same technology was assumed. These studies quantify ZIKV inactivation in platelet components using amotosalen/ultraviolet A.
STUDY DESIGN AND METHODS:
Platelet components were spiked with ZIKV, and ZIKV infectious titers and RNA loads were measured by cell culturebased assays and real-time polymerase chain reaction in spiked platelet components before and after photochemical treatment using amotosalen/ultraviolet A.
RESULTS:
The mean ZIKV infectivity titers and RNA loads in platelet components before inactivation were either 4.9 log 10 plaque forming units per milliliter, or 4.4 log 10 50% tissue culture infective dose per milliliter and 7.5 log 10 genome equivalents per milliliter, respectively. No infectivity was detected immediately after amotosalen/ultraviolet A treatment. No replicative virus remained after treatment, as demonstrated by multiple passages on Vero cell cultures; and ZIKV RNA was not detected from the first passage after inactivation. Additional experiments in this study demonstrated efficient inactivation to the limit of detection in platelets manufactured in 65% platelet additive solution, 35% plasma, or 100% plasma.
CONCLUSION:
As previously demonstrated for plasma, robust levels of ZIKV inactivation were achieved in platelet components. With inactivation of higher levels of ZIKV than those reported in asymptomatic, RNAreactive blood donors, the pathogen-inactivation system using amotosalen/ultraviolet A offers the potential to mitigate the risk of ZIKV transmission by plasma and platelet transfusion. Z ika virus (ZIKV) is a single-stranded RNA arbovirus that, like the West Nile (WNV), dengue (DENV), and yellow fever viruses, is a member of the Flaviviridae family. ZIKV was discovered in a sentinel primate in Africa in 1947. Until the 2007 outbreak in Yap, ZIKV had not been associated with large epidemics or severe disease outcomes. From 2007 to late 2016, it spread quickly, and active ZIKV transmission was reported in 76 countries, including most of the Latin America and Caribbean regions as well as parts of Asia, the Pacific, Africa, and the contiguous United States. 1 Most ZIKVinfected patients are asymptomatic or present with only mild symptoms. 2 However, with the emergence of ZIKV in
French Polynesia in 2013 and in Latin America in 2015 came reports of serious neurologic complications in adults (especially Guillain-Barre syndrome) and severe congenital syndromes (especially microcephaly) after maternal infection during pregnancy.
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ZIKV is primarily transmitted by Aedes mosquitoes. However, the demonstration of nonvector-borne transmission through sexual contact and the transfusion of contaminated blood products has raised concerns over the safety of the blood supply in areas with epidemic and endemic ZIKV.
2 When comparing ZIKV with other arboviruses (Table 1) , [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] infection results in a high percentage of asymptomatic viremic carriers, similar to DENV and WNV but unlike chikungunya virus (CHIKV). Notably, ZIKV, like WNV, causes various neurologic symptoms. The asymptomatic period after a mosquito bite and the severity and frequency (approximately 20%-50%) of typical symptoms for ZIKV are comparable to those for DENV and WNV, which may explain why all three have had transfusion-transmitted cases documented, in contrast to CHIKV infections, which are approximately 80% symptomatic and thus are easily detected by screening. Nonetheless, it is surprising that, despite the extensive CHIKV epidemics to date, no cases of transfusion transmission (TT) have been documented yet, implying that an active rather than passive hemovigilance system may be needed for that. Despite the differences observed, there are clear similarities across the four viruses, which share similar genome sizes and modes of transmission. The much more prevalent sexual transmission for ZIKV complicates the identification of "high-risk" donors and makes the ability to truly monitor asymptomatic individuals in the general population challenging, with the potential for "silent" epidemics. Therefore, screening the blood donor population with nucleic acid testing (NAT) assays may have the additional benefit of monitoring the underlying disease in the various locales of a country. The potential for ZIKV TT was suspected in French Polynesia after 2.8% of blood donors were identified as ZIKV RNA-positive while asymptomatic. 13, 14 This potential was confirmed in Brazil with two reports of probable ZIKV TT after the transfusion of platelet components (PCs) ( Table 1) . 8, 9 In turn, this led public agencies, including the US Food and Drug Administration (FDA), 15, 16 the World Health Organization, 17 and the AABB (formerly the American Association for Blood Banks), 18 to release guidelines for the blood bank industry to prevent ZIKV TT. Several mitigation strategies were proposed, including the use of pathogen inactivation/reduction (PI) technologies, which are currently only approved for the treatment of plasma and PCs, and implementation of NAT for the screening of individual blood donations.
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PI is a proactive method designed to reduce or eliminate the infectivity of pathogens in blood products. 20 Among the processes that inactivate arboviruses, the photochemical treatment of blood components using a psoralen (amotosalen, S-59) in combination with ultraviolet A (UVA) illumination, 21 has been shown to inactivate high 25 and ZIKV 26, 28 and DENV-1 27 in plasma.
In this study, we investigated the inactivation of ZIKV in PCs using amotosalen/UVA treatment. Spiking experiments using high levels of ZIKV in PCs were conducted to demonstrate the efficacy of the INTERCEPT Blood System (Cerus Corporation) for inactivation of ZIKV. Our experimental protocol was based on the prior approach for inactivation of DENV 27 and ZIKV 26, 28 in plasma using five cell culture passages to detect residual replicative viruses and viral titration by endpoint dilution assay (50% tissue culture infectious dose [TCID 50 ]/mL). In addition, the results were compared with the methodology applied in studies used for regulatory claims for pathogen reduction/PI systems using plaque assays (plaque-forming units [pfu]/ mL). Such experiments were performed in PCs manufactured in different media to investigate whether the composition of the suspension medium or the presence of leukocytes affects the extent of inactivation by the amotosalen/UVA pathogen reduction technology in PCs.
MATERIALS AND METHODS

Experimental design
Because French Polynesia is a highly endemic area for arboviruses, to reduce the risk of neutralization by preexisting anti-flavivirus antibodies in donor blood, PCs were collected in the United States, tested for the absence of antibodies against flaviviruses, inoculated with ZIKV, and treated at Cerus Corporation. Nontreated and pretreatment controls, as well as post-treatment test samples, were sent to the Institut Louis Malarde (Tahiti, French Polynesia) frozen on dry ice for determination of infectious viral titers by endpoint dilution assay and RNA loads after passages in cell culture, while retained aliquots were also assayed with the plaque assay.
Virus
In 2013, the ZIKV strain (PF13/251013-18) was isolated in serum from a French Polynesian patient. 29 ZIKV was propagated in African green monkey kidney cells (clone 76, Vero76; American Type Culture Collection) and grown at 378C in an atmosphere of 5% CO 2 in minimum essential medium with Earle's salts (Mediatech) supplemented with 2.5 to 5% fetal bovine serum (FBS) (Tissue Culture Biologicals), 2% penicillin-streptomycin (Mediatech), 1.8% sodium bicarbonate 7.5% (Mediatech), 4 mM L-glutamine (Mediatech), and 1% nonessential amino acids (Mediatech). High titer concentrates were generated from the cell culture supernatants using Centricon Plus-70 centrifugal filter devices (Millipore), as previously described, 30 and were stored at 2808C with 20% FBS. A sample of the virus was sequenced to confirm its identity by comparison it with the original sequencing 25 (Genomics Sequencing Laboratory). Alternatively, ZIKV strain PRVABC59 (Centers for Disease Control and Prevention), which was isolated in Puerto Rico in 2015, was used. The virus was propagated as described above; however, because it is capable of growing to higher titers, the cell culture supernatants generated were not concentrated. Collected supernatants were clarified to remove any cellular debris, aliquoted, and stored at 2808C.
Platelet processing
Apheresis PCs prepared in 65% platelet additive solution (PAS) and 35% plasma were collected by Suncoast Blood Bank before the US Zika epidemic. To ensure the absence of DENV and WNV antibodies (flaviviruses known to circulate in the United States), plasma supernatant isolated from each donation was tested for the presence of anti-WNV and anti-DENV immunoglobulin M (IgM) and IgG antibodies, as previously described, 28, 31 and only PCs that were confirmed as negative were used.
Inoculation of PCs with ZIKV and inactivation process
An approach similar to that described previously for plasma was followed (Fig. 1) . 27, 28 Briefly, four PCs (units A, B, C, and D) were inoculated with concentrated stock ZIKV. One sample was collected from each unit (preinactivation samples) and immediately frozen at 2808C. PCs A, B, and C were transferred into plateletprocessing sets (INTERCEPT Small Volume Set for platelets; Cerus Corporation) containing 15 mL of 6-mM amotosalen solution and exposed to 3 J/cm 2 UVA light using a commercial illuminator (Cerus Corporation) according to the manufacturer's instructions. Unit D was "mock-treated" with 15 mL saline and was not exposed to UVA treatment, thus serving as a positive control. All PCs (A, B, C, and D) were transferred into a container with a compound adsorption device (CAD) designed to remove residual amotosalen and were incubated at 228C for 4 hours.
A sample from each inactivated platelet unit (inactivated samples) and from the positive control (noninactivated sample) were then collected and stored at 2808C until infectious viral titers were determined by endpoint dilution assays and RNA loads after passages in cell culture. Several independent inactivation studies were also performed in PCs manufactured in either 35% plasma/65% PAS or 100% plasma, with or without leukoreduction that met treatment criteria for the INTERCEPT System for platelets. Each of these components was inoculated with ZIKV (strain PRVABC59) as described above, transferred to the appropriate INTERCEPT processing sets, and treated according to the manufacturer's instructions. For these a b Fig. 1 . Experimental design. (a) Endpoint titration/passage approach. Four units of platelets suspended in 65% platelet additive solution (Units A, B, C, and D) were inoculated with a ZIKV stock at 1:100 dilution. Three PCs (Units A, B, and C) were treated with amotosalen and UVA and then exposed to the CAD for 4 hours. The PC unit D was "mock-treated," received an equal volume of saline in lieu of amotosalen, was not subjected to UVA illumination, and was then exposed to CAD. Pre-inactivation samples and inactivated or noninactivated samples were collected from each platelet unit and stored at 2808C until infectious viral titers were determined and RNA loads were performed. Samples were passaged five times, and the samples taken were analyzed for viral infectivity and the presence of viral RNA. (b) Plaque assay approach. PCs manufactured in either 100% plasma or 65% PAS were inoculated with a ZIKV stock at 1:100 dilution. Units were dosed with amotosalen, and "preinactivation samples" were taken. Units were then illuminated with UVA according to the manufacturer's instructions, and "inactivated" samples were taken. The CAD step was not performed in these studies. Preinactivation samples and inactivated or noninactivated samples were collected from each platelet unit and stored at 2808C until infectious viral titers were determined and RNA loads were performed. [Color figure can be viewed at wileyonlinelibrary.com] studies, preinactivation samples were collected after the addition of amotosalen but before UVA illumination. It has been demonstrated that the addition of amotosalen without UVA does not impact the viral titer in blood products (data not shown). Inactivated samples were collected immediately after illumination (units were not incubated with a CAD). All collected samples were stored at 2808C until viral titers were determined by a plaque assay.
Scaled-down (1:20) experiments were also conducted to enable higher input titers of ZIKV. Fifteen milliliters of platelets was inoculated with a 1:100 dilution of ZIKV stock (strain PRVABC59) and dosed with amotosalen at a final concentration of 150 lM. The platelets were then transferred to six-well plates at 2 mL per well and dosed with 3.0 J/cm 2 of UVA. Pre-inactivation samples were collected after the addition of amotosalen but before UVA illumination. Inactivated samples were collected immediately after illumination. All samples were stored at 2808C until viral titers were determined by a plaque assay.
Detection of replicative ZIKV and viral titration
Detection of replicative ZIKV and viral titration was performed as previously described. 27, 28 Briefly, preinactivation, postinactivation, and non-inactivation samples were inoculated in triplicate on Vero cells in 24-well plates, and five successive passages were performed. For each passage, inoculated cells were maintained at 378C in an atmosphere of 5% CO 2 for 4 to 5 days. After each passage, ZIKV-infected cells were detected with an indirect immunofluorescence assay using anti-flavivirus mouse antibodies 4G2 (Institut Pasteur) at 1:50 dilution in phosphate-buffered saline (PBS) (Biomerieux) and goat anti-mouse IgG secondary fluorescein isothiocyanateconjugate antibody (Life Technologies) at a dilution of 1:50 in PBS with Evans blue.
For viral titration, triplicate ten-fold dilutions of all samples were inoculated on Vero cells in 96-well plates and maintained at 378C in an atmosphere of 5% CO 2 for 6 days. ZIKV-infected cells were detected by enzyme-linked immunosorbent assay using antibodies 4G2 at a dilution of 1:2000 and goat anti-mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology) diluted 1:1000 in PBS with 5% skimmed milk (Regilait) and 0.3% Tween-20 (Merck). After incubation with peroxidase substrate tetramethylbenzidine for 5 minutes at room temperature in the dark and the addition of tetramethylbenzidine stop solution (KPL, Inc.), absorbance was read at a wavelength of 450 nm (optical density 450) using a microplate photometer (Thermo Scientific). Wells with ZIKV-positive cells were enumerated for each dilution, and viral titers were expressed as TCID 50 /mL using the method of Reed and Muench. 32 ZIKV infectious titers were also determined by a validated plaque assay that is typically used for regulatory claim studies. Ten-fold dilutions of all samples were inoculated on Vero76 cells in six-well plates and incubated for 1 hour at 378C in an atmosphere of 5% CO 2 . After incubation, the inoculum was removed, and the cells were overlaid with a 1:1 mixture of 2 3 minimum essential medium with Earle's salts supplemented with 2% FBS (Tissue Culture Biologicals), 4% penicillin-streptomycin (Mediatech), 3.6% sodium bicarbonate 7.5%, 8 mM L-glutamine (Mediatech), 2% nonessential amino acids (Mediatech), and 2.4% Avicel RC-581 (FMC Corporation). The inoculated cells were maintained at 378C in an atmosphere of 5% CO 2 for 6 days. The overlay was removed, and the cells were stained with 0.02% crystal violet. Plaques were enumerated and viral titers were expressed as pfu/mL.
ZIKV RNA quantification
ZIKV RNA was extracted from 200 mL of each preinactivation, inactivated, noninactivated, and cell supernatant sample using the QIAcube extraction system (Qiagen) and were then quantified by real-time reverse transcription-polymerase chain reaction (RT-PCR), as previously described. 28 RNA loads were expressed in log 10 genome equivalents (GEq)/mL.
ZIKV infectivity time course in PCs
To determine the stability of ZIKV in platelet preparations under standard blood center storage conditions, PCs manufactured in 100% plasma were inoculated with ZIKV (strain PRVABC59) at a 1:100 dilution. Samples were collected immediately after inoculation (Day 0) and daily for a 7-day period. During the storage period, the platelet unit was kept on a platelet shaker at 228C. All samples were stored at 2808C until determination of infectious ZIKV titer by plaque assay.
RESULTS
Detection of replicative ZIKV and ZIKV titration
Pre-inactivation viral titers in treated samples (Units A, B, and C) ranged from 3.62 to 5.26 log 10 TCID 50 /mL (mean, 4.42 6 0.9 log 10 TCID 50 /mL) ( Table 2 ). The titer in the "mock treated" unit (Unit D) was comparable to titers in the preinactivation sample at 4.64 log 10 TCID 50 /mL and the noninactivated sample (T 5 4 hours) at 4.54 log 10 TCID 50 /mL. The similarity of the titers in the preinactivation and untreated samples in Unit D demonstrates that exposure to platelets or to the CAD did not have any impact on ZIKV titers. The same units were also titrated with a plaque assay ( Table 2) . Plaque assay titers of the preinactivation samples (Units A, B, and C) ranging from 4.72 to 5.02 log 10 pfu/mL (mean, 4.91 6 0.2 log 10 pfu/mL) were broadly consistent with the TCID 50 values ( Table 2 ). The titers in the control unit (Unit D) were 4.81 log 10 pfu/mL and 4.60 log 10 pfu/mL in the preinactivation and noninactivated samples, respectively, demonstrating stability of the viral titer over the period of inactivation. In inactivated samples from Units A, B, and C, no ZIKVinfected cells or plaques were detected in any dilution tested using the two titration methods. The culture of preinactivation (Units A, B, and C) and noninactivated (Unit D) samples produced replicative viruses during successive passages, as determined by an indirect immunofluorescence assay (Table 2) , whereas no replicative virus was detected in any of the postinactivation samples over five successive passages on Vero cells (Table 2) .
ZIKV RNA quantitation
For Units A, B, and C, initial viral RNA loads ranged from 7.55 to 8.04 log 10 GEq/mL (mean, 7.78 6 0.2 log 10 GEq/ mL) in preinactivation samples. Initial viral RNA loads in the inactivated samples (Units A, B, and C) ranged from 7.34 to 7.64 log 10 GEq/mL (mean, 7.46 6 0.2 log 10 GEq/ mL) ( Table 3 ). Viral RNA was still detectable immediately after inactivation due to the presence of inactivated virus incapable of replication but was detectable by the amplification of conserved, small (approximately 80 base pairs) nucleic acid sequences. After the first passage of inactivated samples on Vero cells, however, viral RNA from inactivated input virus was no longer detectable, as expected from viral RNA that is not infectious and as demonstrated by the lack of detection of replicative ZIKV. In contrast, there was no decrease in the genomic titers during the passages in preinactivation samples from the treated units (Units A, B, and C), with average passage loads of 8.05 6 0.1 log 10 GEq/mL ( Table 3) . The control Unit D had initial viral RNA loads of 7.98 log 10 GEq/mL and 7.87 log 10 GEq/mL for the preinactivation and noninactivated samples, respectively. During the passages, both preinactivation and noninactivated samples generated high titers of ZIKV, averaging 8.06 6 0.3 log 10 GEq/mL and 7.86 6 0.4 log 10 GEq/mL, respectively.
Single-unit and small-scale studies
Consistent with previous data, ZIKV (both strains) was inactivated to the limit of detection both in platelets suspended in 35% plasma/65% PAS and in platelets suspended in 100% plasma, with preinactivation titers of 5.35 log 10 pfu/mL and 5.15 log 10 pfu/mL, respectively (Table  4) . No infectious plaques were detected in inactivated samples despite the testing of larger volumes.
In an effort to test the limits of inactivation capacity for ZIKV when treated with amotosalen/UVA, small-scale inactivation studies using higher titer ZIKV (strain PRVABC59) were conducted using a 1:20 scaled down method to obtain viral titers in the preinactivation control samples averaging 6.04 6 0.3 log 10 pfu/mL (Table 5) .
Consistent with the full-scale inactivation studies, there was no detectable infectious ZIKV in the inactivated samples even when volumes greater than 1 mL were plated, resulting in log inactivation of greater than 6.04 6 0.3.
Stability of untreated ZIKV in platelet concentrates
ZIKV infectious titers were assessed over 7 days of room temperature incubation after spiking in platelet components in 65% PAS stored under standard blood center conditions. Over the course of 7 days, the titer of infectious ZIKV declined by approximately 1.89 6 0.32 log 10 pfu/mL, with a titer on Day 0 of 4.97 6 0.29 log 10 pfu/mL and a final titer on Day 7 of 3.08 6 0.61 log 10 pfu/mL (Fig. 2) . The presence of infectious ZIKV after a 7-day incubation under standard blood bank storage conditions for PCs highlights the persistence of infectivity over the storage period of a contaminated PC.
DISCUSSION
The rapid spread of ZIKV throughout the Pacific and the Americas with newly described modes of transmissions, the severe congenital syndromes described in neonates born from mothers infected during pregnancy, and the neurologic complications of ZIKV infection in adults all are contributing to the challenges associated with ZIKV epidemics. These, in addition to the lack of available vaccine or therapeutic interventions, have resulted in recommendations and guidelines by national and international public health agencies to identify at-risk populations and mitigate the risk of transmission by blood product transfusion. In French Polynesia, several mitigation strategies were implemented to prevent ZIKV TT. These included a predonation questionnaire, screening of blood donors with ZIKV-specific symptoms, postdonation donor selfreporting of ZIKV-compatible symptoms, and passive quarantine for red blood cells. These strategies may be only partially effective, principally because most infected donors are asymptomatic. 13, 33 A laboratory-developed NAT assay identified a high percentage of ZIKV RNAreactive blood donations from asymptomatic donors. PI of platelets, which was implemented in 2010 to mitigate DENV TT, was in routine use at the time of the ZIKV outbreak.
In addition, in February 2016, the FDA mandated the use of NAT blood screening assays under investigational new drug approval to prevent ZIKV TT unless FDAapproved pathogen-reduction technologies were used for the treatment of plasma or PCs. 15, 34, 35 Available pathogenreduction technologies in the United States included the INTERCEPT Blood System for platelets and plasma and solvent detergent for plasma (Octaplas). Robust inactivation of ZIKV in plasma units had been previously demonstrated using amotosalen/UVA, in line with previously demonstrated effectiveness against other flaviviruses, such as WNV 22 and DENV. 27 By using similar protocols, as previously published for the inactivation of DENV and ZIKV in plasma with amotosalen/UVA, 27, 28 this study demonstrated that the mean inactivation of ZIKV in platelets using the same technology was greater than 4.42 6 0.9 log 10 TCID 50 /mL, corresponding to 7.46 6 0.2 log 10 GEq/ mL (Tables 2 and 3 ). Because inactivation of flaviviruses studies may commonly use either endpoint titration 24, 25 or plaque assay designs, 21,36,37 we used both methodologies to measure the infectious virus before and after inactivation. The results obtained using endpoint titration assays were consistent with those obtained for the same samples using plaque assays (4.91 6 0.2 log 10 pfu/mL) ( Table 2 ). The level of inactivation of ZIKV was in accordance with the recommendations for evaluation of pathogen-reduction efficacy (Tables 3, 4 , and 5). 39 The inactivation of ZIKV was not affected by the composition of the platelet suspension medium, that is, 65% PAS or 100% plasma (Table 4) , and inactivation appeared to be limited by the maximum concentration of input virus attainable in PCs, reaching greater than 6.04 log 10 ( Table  5 ). The demonstration that infectivity of ZIKVcontaminated platelets, if untreated, survives the duration of standard storage conditions (for an allowed duration of up to 7 days) ( Fig. 2) suggests that all PCs should be inactivated regardless of their age. The comparison of inactivation using the full process with a "mock treated" arm ( Fig. 1 ) provides some mechanistic insights into the process by confirming that exposure to the CAD impacts neither the infectivity of the pathogen nor the RNA titer during the process, whereas treatment with the full process is required. In addition, a comparison of the two experimental approaches using endpoint titration or plaque assays showed that amotosalen alone does not have any measurable effect on the titers. Previous work has also shown that viral nucleic acids are stable after UVA illumination if amotosalen is not used. 40, 41 No replicative ZIKV was found in treated PCs, suggesting that platelets can be transfused immediately after PI treatment. As expected, ZIKV RNA remained detectable using small amplicons immediately after inactivation, as reported for the PI of ZIKV in plasma. 28 However, ZIKV infectivity was not detected from the first passage in cells, demonstrating that the inactivated platelets were not infectious. In addition, with robust inhibition of replication, ZIKA RNA was not detectable during serial passages of treated PCs compared with untreated controls. The above observations are consistent with the mechanism of action for amotosalen/UVA and previous studies demonstrating that, although PCR elongation of viral nucleic acid fragments of less than 300 base pairs are not quantitatively inhibited by amotosalen/UVA treatment, the viruses are incapable of initiating infection. 40, 41 The measured mean genomic titers of inactivated ZIKV in this study were higher than the RNA loads found in ZIKV RNA-reactive, asymptomatic blood donors in French Polynesia during 2013 through 2014 (mean, 4.85 log 10 GEq/mL; range, 3.4-6.9 log 10 GEq/mL), as determined using the same PCR methodology, 28 and in Martinique in 2016 (range, 2.09-6.50 log 10 GEq/mL) using a comparable methodology. 42 This indicates that, if the amotosalen/UVA method had been in routine use, it may 
